Core Viewpoint - Rapport Therapeutics, a clinical-stage biotechnology company, is focused on developing small molecule precision medicines for neurological and psychiatric disorders and will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [1]. Company Overview - Rapport Therapeutics is dedicated to discovering and developing small molecule precision medicines specifically for patients with neurological or psychiatric disorders [3]. - The company's founders have made significant discoveries regarding receptor associated proteins (RAPs) in the brain, which underpin Rapport's RAP technology platform [3]. - The precision neuroscience pipeline includes the lead investigational drug, RAP-219, which targets a RAP expressed in specific brain regions, aiming to treat drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain [3]. - Additional programs are in preclinical and late-stage discovery phases, focusing on chronic pain and hearing disorders [3].
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference